{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:46:01Z","timestamp":1789908361113,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jhep.2016.07.007","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T01:04:13Z","timestamp":1473987853000},"page":"S130-S142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S","title":["Second generation direct-acting antivirals \u2013 Do we expect major improvements?"],"prefix":"10.1016","volume":"65","author":[{"given":"Jordan J.","family":"Feld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.07.007_b0005","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/cid\/civ197","article-title":"Hepatitis C virus therapeutic development: in pursuit of \u201cperfectovir\u201d","volume":"60","author":"Dore","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.07.007_b0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2016.07.007_b0015","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0020","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.jhep.2014.09.006","article-title":"Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C","volume":"61","author":"Kumar","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-0034-1371009","article-title":"Interferon-free strategies with a nucleoside\/nucleotide analogue","volume":"34","author":"Feld","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.07.007_b0030","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhep.2016.07.007_b0035","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/AAC.00294-11","article-title":"Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication","volume":"55","author":"Delang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.07.007_b0040","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor","volume":"59","author":"Kati","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.07.007_b0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2016.07.007_b0050","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.07.007_b0055","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3025","article-title":"Naturally occurring HCV NS5A\/B inhibitor resistance-associated mutations to direct-acting antivirals","author":"Nguyen","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.07.007_b0060","doi-asserted-by":"crossref","first-page":"O057","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"Long-term follow-up of treatment-emergent resistance-associated vairantes in NS3, NS5A and NS5B with paritaprevir, ombitasvir and dasabuvir-based regimens","volume":"62","author":"Krishnan","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0065","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.07.007_b0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","article-title":"Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection","volume":"150","author":"Sulkowski","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.007_b0075","article-title":"Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir\/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study","author":"Terrault","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0080","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)31042-4","article-title":"Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: internal analysis of a prospective observational study","author":"Alqahtani","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0090","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30975-2","article-title":"Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter european compassionate use program","author":"Welzel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0105","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.007_b0110","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2893.2012.01586.x","article-title":"Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2\/3","volume":"19","author":"Pianko","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.07.007_b0115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/gut.2010.236158","article-title":"Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2\/3","volume":"61","author":"Thompson","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.07.007_b0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.25631","article-title":"Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner","volume":"56","author":"Clark","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jhep.2015.08.027","article-title":"Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin","volume":"64","author":"Younossi","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0130","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/liv.12861","article-title":"Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy","volume":"35","author":"Al Marzooqi","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.07.007_b0135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1517\/17460441.2012.711312","article-title":"New hepatitis C virus drug discovery strategies and model systems","volume":"7","author":"Hussain","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.jhep.2016.07.007_b0140","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0145","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1128\/AAC.01229-15","article-title":"Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir\/ritonavir","volume":"59","author":"Schnell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.07.007_b0150","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.gtc.2015.07.013","article-title":"Hepatitis C virus: current and evolving treatments for genotype 4","volume":"44","author":"Asselah","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jhep.2016.07.007_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(15)00529-0","article-title":"Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study","author":"Abergel","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.07.007_b0160","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis","volume":"62","author":"Reddy","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0170","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.20793","article-title":"Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy","volume":"42","author":"Everson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.007_b0180","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jhep.2015.11.034","article-title":"Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin\/sofosbuvir treatment","volume":"64","author":"Welker","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2015.07.041","article-title":"Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use","volume":"64","author":"Dyson","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0190","unstructured":"(FDA) FDA. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. In; 2015."},{"key":"10.1016\/j.jhep.2016.07.007_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30147-1","article-title":"RUBY-I: Ombitasvir\/paritaprevir\/ritonavir+dasabuvir\u00b1RIBAVIRIN in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease","author":"Pockros","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2012.01590.x","article-title":"A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C","volume":"19","author":"Jacobson","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.07.007_b0205","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","article-title":"Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection","volume":"313","author":"Poordad","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.07.007_b0210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0215","article-title":"No scientific basis to restrict 8 weeks of treatment with ledipasvir\/sofosbuvir to patients with HCV RNA <6,000,000IU\/ml","author":"O\u2019Brien","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0220","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.27641","article-title":"Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus","volume":"61","author":"van de Ven","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0225","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0230","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7326\/L15-0485","article-title":"Hepatitis C virus treatment and persons who inject drugs","volume":"164","author":"Grebely","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12371","article-title":"Estimates on HCV disease burden worldwide - filling the gaps","volume":"22","author":"Wedemeyer","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.07.007_b0240","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0245","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0250","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.07.007_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0260","doi-asserted-by":"crossref","first-page":"S1047","DOI":"10.1016\/S0016-5085(16)33538-7","article-title":"High SVR rate with ABT-493+ABT530 for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection","volume":"150","author":"Muir","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.007_b0265","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0270","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30ml\/min","volume":"36","author":"Nazario","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.07.007_b0275","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.07.007_b0280","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0285","article-title":"Short-duration treatment with sofosbuvir\/velpatasvir plus GS-9857 in treatment-na\u00efve genotype 1\u20136 HCV-infected patients with or without cirrhosis","author":"Gane","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0290","article-title":"High efficacy of sofosbuvir\/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype 1\u20136 HCV infected patients including those previously treated with direct-acting antivirals","author":"Gane","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0295","article-title":"ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high genetic barrier to resistance","author":"Ng","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0300","article-title":"100% SVR4 in HCV genotype 1 non-cirrhotic treatment-na\u00efve or -experienced patients with the combination of ABT-493 and ABT-530 for 8 weeks (SURVEYOR-I) [8 weeks]","author":"Poordad","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0305","article-title":"SURVEYOR-II: High SVR4 rates achieved with the next generation NS3\/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-na\u00efve and treatment-experienced patients with HCV genotype 3 infection","author":"Kwo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00170-7","article-title":"100% SVR with ABT-493 and ABT-530 with or without ribavirin in treatment-naive HCV genotype 3-infected patients with cirrhosis","author":"Kwo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(13)60805-3","article-title":"Relationship Between Transaminase Levels and Plasma Pharmacokinetics Following Administration of MK-5172 With Pegylated Interferon Alfa-2b and Ribavirin to HCV Genotype 1 Treatment-Na\u00efve Patients","author":"Caro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30013-1","article-title":"C-SWIFT: grazoprevir\/elbasvir+sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks","author":"Poordad","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0325","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0330","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01699-8","article-title":"Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir\/daclatasvir with or without ribavirin - 6 and 12 month outcomes compared to untreated patients","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0340","doi-asserted-by":"crossref","unstructured":"Welzel TM, Herzer K, Ferenci P, Petersen J, Gschwantler M, Cornberg M, Berg T, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program international liver congress, European Association for the Study of the Liver 2015, Vienna, Austria, 2015.","DOI":"10.1016\/S0168-8278(15)30975-2"},{"key":"10.1016\/j.jhep.2016.07.007_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30149-5","article-title":"Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER","author":"Pol","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0350","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0355","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0360","article-title":"Safety and efficacy of treatment with sofosbuvir+GS-5816\u00b1ribavirin for 8 or 12 weeks in treatment-na\u00efve patients with genotype 1\u20136 HCV infection","author":"Tran","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30157-4","article-title":"Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir\/GS-5816 in treatment-na\u00efve and DAA-experienced genotype 1 patients with and without cirrhosis","author":"Gane","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0370","article-title":"Complete cure after three weeks of all-oral triple-direct acting antiviral (DAA) regimens in non-cirrhotic chronic hepatitis C genotype 1b Chinese subjects (SODAPI STUDY)","author":"Lau","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0375","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(15)30153-7","article-title":"A single dose of RG-101, a GalNAc-conjugated oligonucleotide targeting mir-122, results in undetectable HCV RNA levels in chronic hepatitis C patients at week 28 of follow-up","author":"Van Der Ree","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)01665-2","article-title":"RG-101 in combination with 4 weeks of oral diract acting antiviral therapy achieves high virologic response rates in treatment-naive gneotype 1 and 4 chronic hepatitis C patients: interim results from a randomised, multicenter, phase 2 study","author":"Horvath","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0390","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0395","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.007_b0400","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/ci400060j","article-title":"Computational study on the drug resistance mechanism against HCV NS3\/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis","volume":"54","author":"Xue","year":"2014","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.jhep.2016.07.007_b0405","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nature15711","article-title":"Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A","volume":"527","author":"Sun","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2016.07.007_b0410","doi-asserted-by":"crossref","first-page":"O005","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir-based regimens with Ledipasvir\/Sofosbuvir for 24 weeks","volume":"62","author":"Lawitz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.007_b0415","article-title":"C-SWIFT retreatment (Part B): 12 weeks of elbasvir\/grazoprevir with sofosbuvir and ribavirin successfully treated G1-infected subjects who failed short-duration all-oral therapy","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.007_b0420","article-title":"High efficacy of ABT-493 and ABT-530 in HCV genotype 1 infected patients who have failed direct-acting antviral-containing regimens: The Magellan-I Study","volume":"GS11","author":"Poordad","year":"2016","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2017.02.015","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816303312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816303312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T11:47:08Z","timestamp":1568375228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816303312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0168827816303312"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.07.007","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jhep.2017.02.015","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second generation direct-acting antivirals \u2013 Do we expect major improvements?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}